You are here

FDA Approves Flonase Sensimist as OTC Allergy Treatment

The product was previously available by prescription as Veramyst

The FDA has approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5-mcg spray, GlaxoSmithKline) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.

Flonase Sensimist is indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis, including sneezing, runny nose, itchy nose, congestion, and itchy, watery eyes, in adults and children 2 years of age and older. The indication for itchy, watery eyes is for individuals 12 years of age and older.

Fluticasone furoate acts on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

Flonase Sensimist will be nationally available in early 2017.

Source: PR Newswire; August 3, 2016.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes